Equities

GenixPharmaceucticals Corporation

GENX:CVE

GenixPharmaceucticals Corporation

Actions
  • Price (CAD)0.16
  • Today's Change0.005 / 3.23%
  • Shares traded29.00k
  • 1 Year change220.00%
  • Beta-0.6038
Data delayed at least 15 minutes, as of May 28 2020 15:56 BST.
More ▼

Profile data is unavailable for this security.

About the company

Genix Pharmaceuticals Corporation, formerly Alta Natural Herbs & Supplements Ltd, is a dietary supplements and neutraceuticals company. It manufactures and converts dietary supplements and neutraceuticals (herbal, botanical and marine-based) for the natural healthcare products industry. It develops and manufactures a range of dietary supplements and neutraceuticals for the supplement industry. It is a contract manufacturer/converter of raw material powders, with all conversion, from powders to capsules to bottling and packaging. Its raw material powders are encapsulated in hard gelatin or vegetarian capsules. It engages in the contract manufacturing of dietary supplements for a range of customers ranging from naturopathic practitioners to chains. It operates a Cafe, which serves health meals, drinks, function foods and supplies nutrition supplements. It produces and distributes various dietary supplements into Hong Kong, South Korea, Germany and Italy.

  • Revenue in CAD (TTM)56.99k
  • Net income in CAD-164.71k
  • Incorporated1998
  • Employees--
  • Location
    GenixPharmaceucticals Corporation3512 Rosemary Heights CresSURREY V3Z 0M4CanadaCAN
  • Phone+1 60 4710 9461
  • Fax+1 60 4710 9461
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
iCo Therapeutics Inc0.00-1.94m6.92m5.00--10.47-----0.0156-0.01560.000.00430.00-------235.44-67.04-10,720.35-84.68------------0.00-------13.84------
Hemostemix Inc0.00-6.34m7.02m-----------0.0211-0.02110.00-0.00580.00-------313.14---681.72-------------1,949.09---------79.13------
Devonian Health Group Inc2.37m-4.05m8.10m----1.07--3.42-0.0595-0.05950.03480.12160.1275-1.441.97---21.79---25.93--111.32---170.96--0.4162-8.940.3699--87.44--6.52------
GenixPharmaceucticals Corporation56.99k-164.71k8.14m--------142.83-0.0044-0.00440.0015-0.00210.5561--0.9993---160.72-43.25-6,736.61-63.85-45.0826.36-289.02-35.67---7.19-----67.28-18.11-553.57------
Medcolcanna Organics Inc-100.00bn-100.00bn8.20m----1.13----------0.0793------------------------7.40--0.041--------------
Vaxil Bio Ltd0.00-1.15m8.79m-----------0.013-0.0130.00-0.00660.00-------210.78-----------------103.91---------10.22------
Nuvo Pharmaceuticals Inc79.36m13.85m9.34m91.000.78450.40740.40060.11771.051.054.882.010.44252.394.38872,054.907.723.358.623.9566.7158.3717.459.402.09--0.8437--247.7639.73154.62-38.62-18.01--
NeutriSci International Inc96.55k-1.61m9.37m--------97.05-0.0141-0.01410.0008-0.00130.18250.405620.05---304.78-224.62-2,698.24-568.913.05-0.0438-1,670.50-2,589.260.2133------16.79--32.31------
Data as of May 28 2020. Currency figures normalised to GenixPharmaceucticals Corporation's reporting currency: Canadian Dollar CAD
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.